These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 25534488)
1. Effect of Mechanism of Action of Different ω-6/ω-3 Polyunsaturated Fatty Acids Ratio on the Growth of Endometrial Carcinoma Mice. Lu X; Ding X; Jing L Cell Biochem Biophys; 2015 Apr; 71(3):1671-6. PubMed ID: 25534488 [TBL] [Abstract][Full Text] [Related]
2. Effects of polyunsaturated fatty acids on endometrial carcinoma Ishikawa cells. Lu XY; Zeng T Eur Rev Med Pharmacol Sci; 2014; 18(21):3311-4. PubMed ID: 25487944 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. Zheng H; Tang H; Liu M; He M; Lai P; Dong H; Lin J; Jia C; Zhong M; Dai Y; Bai X; Wang L Cancer Prev Res (Phila); 2014 Aug; 7(8):824-34. PubMed ID: 24866178 [TBL] [Abstract][Full Text] [Related]
4. Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production. Pan J; Cheng L; Bi X; Zhang X; Liu S; Bai X; Li F; Zhao AZ Sci Rep; 2015 Oct; 5():14958. PubMed ID: 26468779 [TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032 [TBL] [Abstract][Full Text] [Related]
7. Elevation of n-3/n-6 PUFAs ratio suppresses mTORC1 and prevents colorectal carcinogenesis associated with APC mutation. Liu M; Zhou L; Zhang B; He M; Dong X; Lin X; Jia C; Bai X; Dai Y; Su Y; Zou Z; Zheng H Oncotarget; 2016 Nov; 7(47):76944-76954. PubMed ID: 27769066 [TBL] [Abstract][Full Text] [Related]
8. lncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR. Du Y; Wang L; Chen S; Liu Y; Zhao Y Mol Carcinog; 2018 Sep; 57(9):1191-1200. PubMed ID: 29745433 [TBL] [Abstract][Full Text] [Related]
9. A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer. Apte SA; Cavazos DA; Whelan KA; Degraffenried LA Nutr Cancer; 2013; 65(4):556-62. PubMed ID: 23659447 [TBL] [Abstract][Full Text] [Related]
10. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683 [TBL] [Abstract][Full Text] [Related]
11. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice. Zhang Y; Xu F; Liang H; Cai M; Wen X; Li X; Weng J Oncol Rep; 2016 Mar; 35(3):1340-8. PubMed ID: 26648451 [TBL] [Abstract][Full Text] [Related]
12. Expression of phosphorylated Akt, mTOR and MAPK in type I endometrial carcinoma: clinical significance. Kourea HP; Nikolaou M; Tzelepi V; Adonakis G; Kardamakis D; Tsapanos V; Scopa CD; Kalofonos C; Decavalas G Anticancer Res; 2015 Apr; 35(4):2321-31. PubMed ID: 25862896 [TBL] [Abstract][Full Text] [Related]
13. mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression. Chen Z; Zhang Y; Jia C; Wang Y; Lai P; Zhou X; Wang Y; Song Q; Lin J; Ren Z; Gao Q; Zhao Z; Zheng H; Wan Z; Gao T; Zhao A; Dai Y; Bai X Oncogene; 2014 Sep; 33(37):4548-57. PubMed ID: 24096482 [TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023 [TBL] [Abstract][Full Text] [Related]
15. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Shin SY; Lee KS; Choi YK; Lim HJ; Lee HG; Lim Y; Lee YH Carcinogenesis; 2013 Sep; 34(9):2080-9. PubMed ID: 23689352 [TBL] [Abstract][Full Text] [Related]
16. Fructus ligustri lucidi extracts induce human glioma cell death through regulation of Akt/mTOR pathway in vitro and reduce glioma tumor growth in U87MG xenograft mouse model. Jeong JC; Kim JW; Kwon CH; Kim TH; Kim YK Phytother Res; 2011 Mar; 25(3):429-34. PubMed ID: 20737659 [TBL] [Abstract][Full Text] [Related]
17. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121. Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881 [TBL] [Abstract][Full Text] [Related]
18. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725 [TBL] [Abstract][Full Text] [Related]
19. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]